THERAVECTUS, a biotechnology company specializing in discovering and developing therapeutic vaccines, recently released its latest encouraging findings from its Phase I and II lentiviral vector-based vaccine study.
This is the first vaccine study of a virus’s response to lentiviral vectors. The researchers’ goal is to compare the patients’ immune responses to highly active antiretroviral therapy (HAART) treatments to the placebo.
The trial is studying two groups, one placebo and one controlled, in 12 different sites in France and Belgium. It includes 38 patients diagnosed with HIV and studies their response to HAART.
As part of the study, the patients receive three different doses of the therapeutic vaccine. Two of the doses are given through intramuscular injections containing non-replicative, self-inactivating lentiviral vectors. These antigens, patented by THERAVECTYS, are specific to HIV.
The study’s findings show that there have been no serious negative side effects for any of the 38 patients involved in the study. Researchers discovered that even the lowest dose produced positive effects.
As there are also no safety concerns about the vaccine, THERAVECTYS researchers look forward to the next step of the vaccine’s development. They plan to apply the information gained from this study to an HTLV-1-induced adult patient with T-cell leukemia/lymphoma. They also plan to work with regulatory agencies to further develop the company’s CAR T-cells.
The study officially ends in December 2014.